Basic and clinical studies of tazobactam/piperacillin in the urological field

Toshihide Hayashi, Toyohiko Watanabe, Tadasu Takenaka, Kouji Sakuramoto, Kazuhiro Hata, Noriaki Ono, Hiromi Kumon, Hiroyuki Ohmori, Katsuyoshi Kondo, Yasuhiro Katayama, Teruaki Akaeda, Shunji Hayata, Toshihiko Asahi, Daisuke Yamada

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We studied the antibacterial activity and clinical efficacy of a new combined drug, tazobactam/piperacillin (TAZ/PIPC), prepared at a ratio of 1: 4, in the urological field. 1) Antibacterial activity: We measured the MICs of TAZ/PIPC against clinical isolates (206 strains of 14 species) from urinary tract infections, and compared them with those of piperacillin (PIPC), sulbactam/cefoperazone (SBT/CPZ), latamoxef (LMOX), and ceftazidime (CAZ). Against gram-positive bacteria, the antibacterial activity of TAZ/PIPC was almost equal to that of PIPC, but was superior to that of other control drugs, whereas against Staphylococcus epidermidis, the activity of TAZ/PIPC was inferior to that of SBT/CPZ. Against gram-negative bacteria the antibacterial activity of TAZ/PIPC was almost equal to that of SBT/CPZ and equal to or twice that of PIPC but inferior to that of LMOX and CAZ. 2) Clinical efficacy: According to the criteria of the Japanese UTI Committee, the overall clinical efficacy rate was 73.3%(22/30) for chronic complicated UTI. Bacteriologically, 38 of 48 strains (79.2%) were eradicated. 3) Side effects: No subjective side effects were observed in this investigation. Liver dysfunction in three cases and eosinophilia in one case were observed, but these were not severe.

Original languageEnglish
Pages (from-to)541-552
Number of pages12
JournalCHEMOTHERAPY
Volume42
DOIs
Publication statusPublished - Jan 1 1994

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Fingerprint Dive into the research topics of 'Basic and clinical studies of tazobactam/piperacillin in the urological field'. Together they form a unique fingerprint.

  • Cite this

    Hayashi, T., Watanabe, T., Takenaka, T., Sakuramoto, K., Hata, K., Ono, N., Kumon, H., Ohmori, H., Kondo, K., Katayama, Y., Akaeda, T., Hayata, S., Asahi, T., & Yamada, D. (1994). Basic and clinical studies of tazobactam/piperacillin in the urological field. CHEMOTHERAPY, 42, 541-552. https://doi.org/10.11250/chemotherapy1953.42.Supplement2_541